{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:38:40Z","timestamp":1791027520355,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.nmd.2006.08.012","type":"journal-article","created":{"date-parts":[[2006,11,29]],"date-time":"2006-11-29T17:25:15Z","timestamp":1164821115000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue"],"prefix":"10.1016","volume":"17","author":[{"given":"Leah J.","family":"Harcourt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Schertzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Ryall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon S.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2006.08.012_bib1","first-page":"491","article-title":"Viral vectors for gene transfer to striated muscle","volume":"6","author":"Gregorevic","year":"2004","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.nmd.2006.08.012_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ymthe.2005.11.001","article-title":"Gene therapy strategies for duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors","volume":"13","author":"Blankinship","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2006.08.012_bib3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/13543776.11.4.587","article-title":"Novel therapies for muscular dystrophy","volume":"11","author":"Lynch","year":"2001","journal-title":"Expert Opin Ther Patents"},{"key":"10.1016\/j.nmd.2006.08.012_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00003677-200110000-00002","article-title":"Therapies for improving muscle function in neuromuscular disorders","volume":"29","author":"Lynch","year":"2001","journal-title":"Exerc Sport Sci Rev"},{"key":"10.1016\/j.nmd.2006.08.012_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1203\/01.PDR.0000145578.01985.D0","article-title":"Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events","volume":"56","author":"Tidball","year":"2004","journal-title":"Pediatr Res"},{"key":"10.1016\/j.nmd.2006.08.012_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01120827","article-title":"Chronic effects of \u03b22-adrenergic agonists on body composition and protein synthesis in rat","volume":"4","author":"Emery","year":"1984","journal-title":"Biosci Rep"},{"key":"10.1016\/j.nmd.2006.08.012_bib7","series-title":"Performance-enhancing substances in sport and exercise","first-page":"47","article-title":"Beta-2 agonists","author":"Lynch","year":"2002"},{"key":"10.1016\/j.nmd.2006.08.012_bib8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1212\/WNL.50.5.1402","article-title":"Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group","volume":"50","author":"Kissel","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2006.08.012_bib9","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/01.WNL.0000118530.71646.0F","article-title":"Pilot study of albuterol in Duchenne and Becker muscular dystrophy","volume":"62","author":"Fowler","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2006.08.012_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjp.0706669","article-title":"Systemic administration of \u03b22-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses","volume":"147","author":"Ryall","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nmd.2006.08.012_bib11","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/0024-3205(93)90729-M","article-title":"Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective \u03b22-adrenoceptor agonist bronchodilator","volume":"52","author":"Anderson","year":"1993","journal-title":"Life Sci"},{"key":"10.1016\/j.nmd.2006.08.012_bib12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0022-3565(24)38060-7","article-title":"Kinetic analysis of drug-receptor interactions of long-acting \u03b22 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase","volume":"28","author":"Teschemacher","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nmd.2006.08.012_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1183\/09031936.94.07030569","article-title":"Why are long-acting beta-adrenoceptor agonists long-acting?","volume":"7","author":"Anderson","year":"1994","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmd.2006.08.012_bib14","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/mus.880181216","article-title":"Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice","volume":"18","author":"Dupont-Versteegden","year":"1995","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2006.08.012_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1440-1681.1994.tb02443.x","article-title":"Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice","volume":"21","author":"Hayes","year":"1994","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib16","doi-asserted-by":"crossref","first-page":"C865","DOI":"10.1152\/ajpcell.1994.267.3.C865","article-title":"Clenbuterol, a \u03b22-agonist, retards wasting and loss of contractility in irradiated dystrophic mdx muscle","volume":"267","author":"Zeman","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1152\/jappl.1996.80.3.734","article-title":"Exercise and clenbuterol as strategies to decrease the progression of muscular dystrophy in mdx mice","volume":"80","author":"Dupont-Versteegden","year":"1996","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib18","first-page":"195","article-title":"Exercise performance in 6-to-11-year-old boys with Duchenne muscular dystrophy","volume":"58","author":"Sockolov","year":"1977","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.nmd.2006.08.012_bib19","first-page":"R961","article-title":"Regenerative capacity of the dystrophic (mdx) diaphragm after induced injury","volume":"287","author":"Matecki","year":"2004","journal-title":"Am J Physiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/jpet.106.107045","article-title":"Chronic treatment with the \u03b22-adrenoceptor agonist pro-drug BRL-47672 impairs rat skeletal muscle function by inducing a comprehensive shift to a faster muscle phenotype","volume":"319","author":"Baker","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nmd.2006.08.012_bib21","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/S0002-9440(10)64502-6","article-title":"Improved contractile fuction of the mdx dystrophic mouse diaphragm muscle following IGF-I administration","volume":"161","author":"Gregorevic","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2006.08.012_bib22","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0002-9440(10)62333-4","article-title":"Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice","volume":"166","author":"Harcourt","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2006.08.012_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2006.03.003","article-title":"Differential calcineurin signalling activity and regeneration efficacy in diaphragm and limb muscles of dystrophic mdx mice","volume":"16","author":"Stupka","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2006.08.012_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00401-003-0807-x","article-title":"Inhibition of the calcineurin signaling pathway with cyclosporine A impairs muscles regeneration in young mdx mice","volume":"107","author":"Stupka","year":"2003","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nmd.2006.08.012_bib25","first-page":"R1386","article-title":"\u03b22-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol","volume":"283","author":"Ryall","year":"2002","journal-title":"Am J Physiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/1097-4598(200102)24:2<211::AID-MUS60>3.0.CO;2-D","article-title":"Clenbuterol reduces soleus muscle fatigue during disuse in aged rats","volume":"24","author":"Chen","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2006.08.012_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0742-8413(95)00066-6","article-title":"Effect of the \u03b22-adrenergic agonist clenbuterol on the growth of fast- and slow-twitch skeletal muscle of the dystrophic (C57BL6J dy2J\/dy2J) mouse","volume":"111","author":"Agbenyega","year":"1995","journal-title":"Comp Biochem Physiol C Pharmacol Toxicol Endocrinol"},{"key":"10.1016\/j.nmd.2006.08.012_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2990.1985.tb00039.x","article-title":"Histochemical fibre typing and ultrastructure of the small fibres in Duchenne muscular dystrophy","volume":"11","author":"Watkins","year":"1985","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib29","first-page":"S15","article-title":"Becker and Duchenne muscular dystrophy: a comparative morphological study","volume":"24","author":"Dennett","year":"1988","journal-title":"Aust Paediatr J"},{"key":"10.1016\/j.nmd.2006.08.012_bib30","first-page":"E726","article-title":"Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a \u03b22-receptor agonist","volume":"254","author":"Zeman","year":"1988","journal-title":"Am J Physiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.0001-6772.2003.01246.x","article-title":"Clenbuterol treatment affects myosin heavy chain isoforms and MyoD content similarly in intact and regenerated soleus muscles","volume":"180","author":"Bricout","year":"2004","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.nmd.2006.08.012_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1113\/jphysiol.2003.056770","article-title":"\u03b22-agonist administration reverses muscle wasting and improves muscle function in aged rats","volume":"555","author":"Ryall","year":"2004","journal-title":"J Physiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib33","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1152\/jappl.1998.84.4.1359","article-title":"Myogenin, MyoD, and myosin expression after pharmacologically and surgically induced hypertrophy","volume":"84","author":"Mozdziak","year":"1998","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib34","first-page":"E941","article-title":"Clenbuterol increases the expression of myogenin but not myoD in immobilized rat muscles","volume":"272","author":"Delday","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.nmd.2006.08.012_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0014-5793(96)00910-6","article-title":"No alteration in gene expression of components of the ubiquitin-proteasome proteolytic pathway in dystrophin-deficient muscles","volume":"393","author":"Combaret","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.nmd.2006.08.012_bib36","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-04-0425","article-title":"Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting","volume":"64","author":"Busquets","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.nmd.2006.08.012_bib37","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/mus.20504","article-title":"Dose-dependent separation of the hypertrophic and myotoxic effects of the \u03b22-adrenergic receptor agonist clenbuterol in rat striated muscles","volume":"33","author":"Burniston","year":"2006","journal-title":"Muscle Nerve"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896606005335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896606005335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:54:29Z","timestamp":1760774069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896606005335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0960896606005335"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2006.08.012","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2006.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}